BioCentury | Oct 3, 2016
Company News

J&J, Tracon deal

...& Johnson’s Janssen Pharmaceutica N.V. unit granted Tracon exclusive, worldwide development rights to TRC253 (formerly JNJ-63576253...
...the deal was announced. In 1H17, Tracon plans to begin a Phase I/II trial of TRC253...
...Following the completion of the trial, Janssen has an exclusive option to reacquire rights to TRC253...
Items per page:
1 - 1 of 1